文献速递胸部肿瘤

肿瘤连接负担与抗原呈递作为免疫检查点抑制剂治疗间皮瘤的生存预测因素

Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors.
PubMed 文献 · J Thorac Oncol · 2021-11-17

研究对44例间皮瘤患者胸膜活检行RNA和全基因组测序,分析染色体易位连接负担与抗原加工呈递基因集表达。肿瘤连接负担本身不预测总生存,但其与抗原加工呈递基因集的交互作用可预测总生存及1.5年以上生存,曲线下面积0.83;该交互作用在未接受免疫检查点抑制剂的患者中不预测生存。

要点

  • 肿瘤连接负担单独不预测免疫检查点抑制剂治疗的间皮瘤患者总生存。
  • 连接负担与抗原加工呈递基因集表达存在显著交互作用,可预测总生存。
  • 该交互作用预测1.5年以上生存的曲线下面积为0.83,未接受免疫检查点抑制剂者中不预测生存。

核心结论

  • 结构变异与抗原呈递基因集表达分析可能有助于筛选适合免疫检查点抑制剂治疗的患者。

研究设计与样本

  • 获取至少一线治疗后间皮瘤患者的胸膜活检标本(n=44),在纳武利尤单抗单药(NCT29908324)或联合伊匹木单抗(NCT30660511)治疗前进行RNA和全基因组测序。
  • 识别染色体易位产生的连接并检测抗原加工呈递基因集表达,采用Cox模型评估与总生存的关联。
  • 以1.5年总生存界值区分有无持久获益,用于受试者工作特征曲线分析。

主要发现

  • 肿瘤连接负担未预测总生存,但连接负担与多个抗原加工呈递基因集之间存在显著交互作用。
  • 「肽抗原加工与呈递调控」基因集与肿瘤连接负担的交互作用可预测总生存。
  • 该交互作用预测1.5年及以上生存的受试者工作特征曲线下面积为0.83。
  • 该交互作用在另一组未接受免疫检查点抑制剂的间皮瘤患者中未预测生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The favorable outcomes with immunotherapy for mesothelioma were somewhat unexpected because this tumor has a low tumor mutation burden which has been associated with benefit in other cancers. Because chromosomal rearrangements are common in mesothelioma and have neoantigenic potential, we sought to determine whether they are associated with survival in patients treated with immunotherapy. METHODS: Pleural biopsies of mesothelioma after at least one line of therapy were obtained from patients (n = 44) before treatment with nivolumab alone (NCT29908324) or in combination with ipilimumab (NCT30660511). RNA and whole-genome sequencing were performed to identify the junctions resulting from chromosomal rearrangements and antigen processing and presentation gene set expression. Associations with overall survival (OS) were estimated using Cox models. An OS cutoff of 1.5 years was used to distinguish patients with and without durable benefit for use in receiving operating characteristic curves. RESULTS: Although tumor junction burdens were not predictive of OS, we identified significant interactions between the junction burdens and multiple antigen processing and presentation gene sets. The "regulation of antigen processing and presentation of peptide antigen" gene set revealed an interaction with tumor junction burden and was predictive of OS. This interaction also predicted 1.5-year or greater survival with an area under the receiving operating characteristic curve of 0.83. This interaction was not predictive of survival in a separate cohort of patients with mesothelioma who did not receive immune checkpoint inhibitors. CONCLUSIONS: Analysis of structural variants and antigen presentation gene set expression may facilitate patient selection for immune checkpoint inhibitors.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kosari F, Disselhorst M, Yin J, et al. Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2021. PMID: 34800701. doi:10.1016/j.jtho.2021.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。